UNLABELLED: The majority of women Veterans using VA (Veterans Administration) care fall in the 45-65 year-old age range. Understanding how menopause is managed in this group is of importance to optimizing their health. OBJECTIVE: National population estimates showed a prevalence of hormone therapy (HT) use by women over 45 years of 4.7 % (2009-2010). Our study described the frequency of HT use among women Veterans in VA, and examined whether mental health (MH) was predictive of HT use. DESIGN: This was a cross-sectional analysis of national VA administrative data for fiscal year 2009. PARTICIPANTS: Women Veterans over the age of 45 (N = 157,195) accessing VA outpatient care were included in the analysis. MAIN MEASURES: Logistic regression analyses using HT use as the dependent variable. KEY RESULTS: Mean age was 59.4 years (SD =12.2, range =46-110), and 16,227 (10.3 %) of all women used HT. Hysterectomy (OR 3.99 [3.53, 4.49]) and osteoporosis (1.34 [1.27, 1.42]) were the strongest medical indicators of HT use. A total of 49,557 (31.5 %) women in the sample received at least one primary diagnosis of a MH disorder and were more likely to use HT than women with no MH diagnoses (unadjusted OR 1.56, 95 % CI [1.50, 1.61]). Women Veterans with a mood disorder (depression/bipolar) or anxiety disorder [post-traumatic stress disorder (PTSD), other anxiety diagnoses] were more likely to use HT after controlling for demographics and medical comorbidity. CONCLUSION: The prevalence of HT use among women Veterans using VA is more than twice that of the general population. Prior work suggested that women Veterans were discontinuing HT at comparable rates, but these data demonstrate that decline in VA HT use has not kept pace with that of civilian medical care. The association of MH diagnosis with HT use suggests that MH plays an important role in VA rates. Further study is needed to understand contributing patient and provider factors.
UNLABELLED: The majority of women Veterans using VA (Veterans Administration) care fall in the 45-65 year-old age range. Understanding how menopause is managed in this group is of importance to optimizing their health. OBJECTIVE: National population estimates showed a prevalence of hormone therapy (HT) use by women over 45 years of 4.7 % (2009-2010). Our study described the frequency of HT use among women Veterans in VA, and examined whether mental health (MH) was predictive of HT use. DESIGN: This was a cross-sectional analysis of national VA administrative data for fiscal year 2009. PARTICIPANTS: Women Veterans over the age of 45 (N = 157,195) accessing VA outpatient care were included in the analysis. MAIN MEASURES: Logistic regression analyses using HT use as the dependent variable. KEY RESULTS: Mean age was 59.4 years (SD =12.2, range =46-110), and 16,227 (10.3 %) of all women used HT. Hysterectomy (OR 3.99 [3.53, 4.49]) and osteoporosis (1.34 [1.27, 1.42]) were the strongest medical indicators of HT use. A total of 49,557 (31.5 %) women in the sample received at least one primary diagnosis of a MH disorder and were more likely to use HT than women with no MH diagnoses (unadjusted OR 1.56, 95 % CI [1.50, 1.61]). Women Veterans with a mood disorder (depression/bipolar) or anxiety disorder [post-traumatic stress disorder (PTSD), other anxiety diagnoses] were more likely to use HT after controlling for demographics and medical comorbidity. CONCLUSION: The prevalence of HT use among women Veterans using VA is more than twice that of the general population. Prior work suggested that women Veterans were discontinuing HT at comparable rates, but these data demonstrate that decline in VA HT use has not kept pace with that of civilian medical care. The association of MH diagnosis with HT use suggests that MH plays an important role in VA rates. Further study is needed to understand contributing patient and provider factors.
Authors: Cynthia A Stuenkel; Margery L S Gass; JoAnn E Manson; Rogerio A Lobo; Lubna Pal; Robert W Rebar; Janet E Hall Journal: Menopause Date: 2012-08 Impact factor: 2.953
Authors: Keren Lehavot; Katherine D Hoerster; Karin M Nelson; Matthew Jakupcak; Tracy L Simpson Journal: Am J Prev Med Date: 2012-05 Impact factor: 5.043
Authors: Chuan-Fen Liu; Chris L Bryson; James F Burgess; Nancy Sharp; Mark Perkins; Matthew L Maciejewski Journal: BMC Health Serv Res Date: 2012-03-05 Impact factor: 2.655
Authors: Jodie G Katon; Laurie Zephyrin; Anne Meoli; Avanthi Hulugalle; Jeane Bosch; Lisa Callegari; Ileana V Galvan; Kristen E Gray; Kristin O Haeger; Claire Hoffmire; Silvina Levis; Erica W Ma; Jennifer E Mccabe; Yael I Nillni; Suzanne L Pineles; Shivani M Reddy; David A Savitz; Jonathan G Shaw; Elizabeth W Patton Journal: Semin Reprod Med Date: 2019-04-19 Impact factor: 1.303
Authors: Rebecca B Lawn; Kristen M Nishimi; Yongjoo Kim; Sun Jae Jung; Andrea L Roberts; Jennifer A Sumner; Rebecca C Thurston; Lori B Chibnik; Eric B Rimm; Andrew D Ratanatharathorn; Shaili C Jha; Karestan C Koenen; Shelley S Tworoger; Laura D Kubzansky Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-12-21 Impact factor: 4.254
Authors: Elisheva R Danan; Erin E Krebs; Kristine Ensrud; Eva Koeller; Roderick MacDonald; Tina Velasquez; Nancy Greer; Timothy J Wilt Journal: J Gen Intern Med Date: 2017-09-14 Impact factor: 5.128